Evidence Generation and Strategic Advisory
Evidence generation is not simply about producing evidence. It is about selecting the right methods, addressing the right questions, and generating evidence that is fit for future decision-making.
Generate Evidence That Supports Better Decisions
Effective evidence generation starts with understanding the decision problem and the evidence needed to support future decision-making. Synthessa helps clients design evidence programmes that remain clinically relevant and aligned with research objectives, supporting activities ranging from targeted literature reviews and systematic reviews through to HTA-aligned evidence packages and publication support.
Services Include
-
Targeted and systematic literature reviews, protocol development, and evidence mapping designed to support specific research, clinical, and HTA objectives.
-
AI-enabled living evidence libraries developed with selected technology partners, combining structured evidence management, automated surveillance, and expert oversight to maintain current and decision-ready evidence.
-
Integrated evidence packages designed to support HTA decision-making, including NICE, the EU JCA, and other global HTA requirements. Evidence strategies are aligned with clinically relevant PICOs and comparative effectiveness considerations.
-
Evidence reviews supporting manuscripts, congress abstracts, posters, scientific communications, and publication development, including independent medical writing services.
Comparative analyses are only as strong as the evidence strategy that underpins them. Synthessa supports the development of clinically relevant PICOs, systematic assessment of treatment effect modifiers, and appropriate methodology selection to ensure comparative analyses are built on transparent, well-justified, and decision-relevant evidence.
Build Comparative Evidence Around Clinically Relevant PICOs
Services Include
-
Comparative effectiveness strategy as part of integrated evidence generation plans. Activities include comparator selection, treatment effect modifier assessment, evidence gap identification, outcome prioritisation, and development of clinically relevant PICOs designed to maximise the feasibility and credibility of future comparative analyses.
-
Systematic identification and assessment of treatment effect modifiers to support comparative effectiveness programmes. Reviews may be targeted or comprehensive depending on programme objectives, timelines, and resource requirements. Assessments can be designed to support specific HTA requirements, including EU JCA and IQWiG best practices, and may incorporate expert validation of clinically relevant variables.
-
Assessment of available evidence sources to determine the feasibility of indirect treatment comparisons. This includes evaluation of network connectivity and geometry, balance of treatment effect modifiers, similarity of shared comparators, outcome consistency, estimand definitions and approaches to intercurrent events, and the availability of individual patient-level data and other relevant evidence sources. Assessments are designed to identify evidence limitations, evaluate methodological suitability, and provide recommendations on the most appropriate comparative effectiveness approach.
-
Comparative effectiveness analyses delivered across anchored and unanchored methodologies, including network meta-analysis, matching-adjusted indirect comparisons, simulated treatment comparisons, multilevel network meta-regression, and analyses using observational individual patient-level data. Synthessa provides strategic oversight, interpretation of findings, and methodological guidance, working alongside a network of trusted statistical partners to ensure analyses remain aligned with research objectives, clinical relevance, and decision-making needs.
Build Evidence Packages for HTA Assessment
Systematically identifying evidence is only one part of successful HTA package. Evidence must be synthesized, structured, and evaluated in a way that aligns with the decision problem and the requirements of different HTA bodies. Synthessa supports the development of evidence packages designed to meet NICE, EU JCA, and other global HTA requirements.
Services Include
-
Assessment of existing HTA evaluations and reimbursement decisions to understand evidence requirements, comparator expectations, and key decision drivers. Findings are used to inform evidence generation plans, systematic literature reviews, comparative effectiveness assessments, and future HTA evidence packages.
-
Development of integrated evidence packages that combine systematic literature reviews of clinical efficacy and effectiveness, economic evaluations, health state utilities, healthcare resource use and costs, and comparative effectiveness assessments. Packages are designed to provide a coherent global evidence foundation aligned with the requirements of NICE, the EU JCA, and other HTA decision-makers.
-
Adaptation of global evidence packages to address local decision problems, evidence requirements, and methodological preferences. Support includes evidence updates, refinement of comparative effectiveness approaches, and alignment of evidence packages with the requirements of individual HTA agencies.
Optimize Evidence Generation Through Technology and Expertise
Technology alone does not improve evidence generation. Success depends on selecting the right tools, designing effective workflows, and ensuring technology aligns with scientific, operational, and evidence generation objectives. Synthessa provides flexible advisory support to technology developers, pharmaceutical companies, and consulting organizations seeking to optimize evidence generation through technology and senior expertise.
Services Include
-
Advisory support for developers of AI-enabled evidence synthesis technologies. Combining expertise across HEOR methodology, product development, and evidence generation operations, Synthessa helps inform use-case development, feature prioritization, scientific validation, workflow design, and product strategy to ensure solutions align with the needs of pharmaceutical companies, evidence generation teams, and HTA stakeholders.
-
Support for pharmaceutical companies and consulting organisations seeking to adopt, evaluate, and optimize evidence synthesis technologies. Activities may include technology evaluation, workflow design, implementation planning, and integration of technology-enabled processes within existing evidence generation workflows, using client-preferred platforms and solutions.
-
Flexible advisory support provided on a time-and-materials basis across evidence generation, comparative effectiveness, HTA evidence development, and technology initiatives. Engagements may include strategic planning, scientific oversight, interim leadership, product advisory roles, methodology review, and specialist expertise tailored to programme needs.
Our Process
Tailored Scoping
A clear scope aligned with your objectives, timelines, and decision-making needs.
Open Dialogue
Regular communication and collaborative decision-making from project initiation to delivery.
Senior-Led Delivery
Senior involvement from project initiation through final delivery.
Trusted Network
Access to trusted specialist partners when additional expertise is required.